PSORAS
MCID: PSR001
MIFTS: 64

Psoriatic Arthritis (PSORAS) malady

Categories: Genetic diseases (common), Skin diseases

Aliases & Classifications for Psoriatic Arthritis

About this section

Aliases & Descriptions for Psoriatic Arthritis:

Name: Psoriatic Arthritis 52 11 25 70 27 38 13
Psoriatic Arthropathy 11 25 70
Arthropathic Psoriasis 11 25
Arthritis, Psoriatic 39 68
Psoriatic Arthritis, Susceptibility to 12
 
Psoriasis Arthropathica 70
Arthritis Psoriatica 11
Arthritic Psoriasis 70
Arthritis Psoriatic 50
Psoras 70

Classifications:



External Ids:

OMIM52 607507
Disease Ontology11 DOID:9008
ICD1030 L40.5, L40.50
ICD9CM32 696.0
MeSH39 D015535
NCIt45 C61277

Summaries for Psoriatic Arthritis

About this section
MedlinePlus:38 Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. you usually get them on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. some people with psoriasis have psoriatic arthritis. it causes pain, stiffness, and swelling of the joints. it is often mild, but can sometimes be serious and affect many joints. the joint and skin problems don't always happen at the same time. your doctor will do a physical exam and imaging tests to diagnose psoriatic arthritis. there is no cure, but medicines can help control inflammation and pain. in rare cases, you might need surgery to repair or replace damaged joints.

MalaCards based summary: Psoriatic Arthritis, also known as psoriatic arthropathy, is related to hepatitis and collagenous colitis, and has symptoms including back pain, muscle cramp and sciatica. An important gene associated with Psoriatic Arthritis is LTA (Lymphotoxin Alpha), and among its related pathways are Canonical NF-kappaB pathway and IL-15 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types. The drugs aurothioglucose and auranofin have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and bone, and related mouse phenotypes are Increased shRNA abundance (Z-score > 2) and Synthetic lethal with MLN4924 (a NAE inhibitor).

Disease Ontology:11 A syndrome that occurs in humans with psoriasis who also experience symptoms similar to arthritis.

Genetics Home Reference:25 Psoriatic arthritis is a condition involving joint inflammation (arthritis) that usually occurs in combination with a skin disorder called psoriasis. Psoriasis is a chronic inflammatory condition characterized by patches of red, irritated skin that are often covered by flaky white scales. People with psoriasis may also have changes in their fingernails and toenails, such as nails that become pitted or ridged, crumble, or separate from the nail beds.

OMIM:52 Psoriasis (177900) is a chronic inflammatory skin disease that may have an autoimmune basis. The disorder has a strong... (607507) more...

UniProtKB/Swiss-Prot:70 Psoriatic arthritis: An inflammatory, seronegative arthritis associated with psoriasis. It is a heterogeneous disorder ranging from a mild, non-destructive disease to a severe, progressive, erosive arthropathy. Five types of psoriatic arthritis have been defined: asymmetrical oligoarthritis characterized by primary involvement of the small joints of the fingers or toes; asymmetrical arthritis which involves the joints of the extremities; symmetrical polyarthritis characterized by a rheumatoid like pattern that can involve hands, wrists, ankles, and feet; arthritis mutilans, which is a rare but deforming and destructive condition; arthritis of the sacroiliac joints and spine (psoriatic spondylitis).

Wikipedia:71 Psoriatic arthritis is a long-term inflammatory arthritis that occurs in people affected by the... more...

Related Diseases for Psoriatic Arthritis

About this section

Diseases related to Psoriatic Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 266)
idRelated DiseaseScoreTop Affiliating Genes
1hepatitis30.4HLA-C, HLA-DRB1, TNF
2collagenous colitis29.8CRP, IL1B, NOD2, S100A12, TNF
3neuropathy29.8CRP, IL1B, TNF
4cryptococcosis29.8HLA-DRB1, TNF, TNFRSF1B
5dermatitis herpetiformis29.8MMP3, TNF, TNFRSF1B
6rheumatoid arthritis29.3COMP, CRP, HLA-DRB1, IL1B, LTA, MMP3
7celiac disease28.8CRP, MMP3, NOD2, TNF, TNFRSF11B, TNFRSF1A
8spondyloarthropathy 111.8
9arthritis11.6
10psoriasis11.6
11psoriatic juvenile idiopathic arthritis11.3
12intussusception10.4IL1B, TNF
13spondylitis10.4
14swine influenza10.3CRP, HLA-DRB1, TNF
15cataract10.3CRP, IL1B, TNF
16pulmonary hemosiderosis10.3HLA-DRB1, LTA, TNF
17amyotrophic lateral sclerosis type 1410.3IL1B, NOD2, TNF
18parkinson disease 1110.3IL1B, NOD2, TNF
19benign neonatal seizures10.3CRP, IL1B, TNF
20meier-gorlin syndrome 310.3IL1B, NOD2, TNF
21functional gastric disease10.3CRP, NOD2, TNF
22plummer's disease10.3CRP, HLA-DRB1, TNF
23urticaria10.3CRP, IL1B, TNF
24nasopharyngitis10.3IL1B, LTA, TNF
25motility-related diarrhea10.3HLA-DRB1, IL1B, TNF
26atrophy of prostate10.3CRP, IL1B, TNF
27kernicterus due to isoimmunization10.3HLA-C, HLA-DRB1, LTA, TNF
28hypotrichosis-lymphedema-telangiectasia-renal defect syndrome10.3IL1B, SELE, TNF
29hidradenitis10.3CRP, HLA-DRB1, IL1B
30right ventricle hypoplasia10.3HLA-DRB1, SELE, TNF
31dermatomycosis10.3CRP, SELE, TNF
32autosomal recessive type iv ehlers-danlos syndrome10.3IL1B, TNF, TNFSF11
33blepharochalasis10.3CRP, IL1B, TNF
34immunoglobulin g deficiency10.3HLA-DRB1, IL1B, TNF
35acute cholangitis10.3HLA-C, HLA-DRB1, TNF
36choroiditis10.3CRP, IL1B, TNF
37carotenemia10.3CRP, MMP3, TNF
38retinal vascular occlusion10.3IL1B, LTA, TNF
39infancy electroclinical syndrome10.3CRP, IL1B, TNF
40rift valley fever10.3CRP, IL1B, LTA, TNF
41migraine with aura10.3IL1B, SELE, TNF
42newcastle disease10.3NOD2, TNF, TNFRSF1B
43unilateral hypoactive labyrinth10.3CRP, IL1B, TNF
44pyelonephritis10.3CRP, IL1B, TNF
45human immunodeficiency virus infectious disease10.3CRP, HLA-DRB1, IL1B, TNF
46colon adenocarcinoma10.3CRP, IL1B, TNF
47blue toe syndrome10.2IL1B, LTA, TNF
48stiff-person syndrome10.2CRP, HLA-DRB1, PTPN22
49orbital osteomyelitis10.2HLA-C, MMP3, TNF, TNFSF11
50anterior corneal pigmentation10.2HLA-C, HLA-DRB1, PTPN22

Graphical network of the top 20 diseases related to Psoriatic Arthritis:



Diseases related to psoriatic arthritis

Symptoms & Phenotypes for Psoriatic Arthritis

About this section


Clinical features from OMIM:

607507

UMLS symptoms related to Psoriatic Arthritis:


back pain, muscle cramp, sciatica

GenomeRNAi Phenotypes related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00366-A-1929.7HLA-C, MICA, NOD2, SELE
2GR00250-A-18.1IL1B, LTA, NOD2, TNF, TNFRSF11B, TNFRSF1A

MGI Mouse Phenotypes related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053709.2LTA, PTPN22, SELE, TNF, TNFRSF1A, TNFRSF1B
2MP:00053889.0IL13, LTA, PTPN22, SELE, TNF, TNFRSF1A
3MP:00107718.9IL13, IL1B, SELE, TNF, TNFRSF1A, TNFRSF1B
4MP:00053908.4COMP, IL13, IL1B, LTA, MMP3, NOD2
5MP:00053858.4COMP, CRP, IL1B, LTA, PTPN22, SELE
6MP:00053788.2COMP, IL13, LTA, NOD2, PTPN22, SELE
7MP:00053767.8COMP, CRP, IL13, IL1B, LTA, MMP3
8MP:00053977.8IL13, IL1B, LTA, MMP3, NOD2, PTPN22
9MP:00053877.5COMP, CRP, IL13, IL1B, LTA, MMP3

Drugs & Therapeutics for Psoriatic Arthritis

About this section

Drugs for Psoriatic Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 166)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
ZincapprovedPhase 422967440-66-632051, 23994
Synonyms:
30Zn
Cinc
Zinc
Zinc ion
 
Zincum
Zink
Zn
Zn(ii)
Zn2+
2
AdalimumabapprovedPhase 4, Phase 3, Phase 2494331731-18-116219006
Synonyms:
331731-18-1
Adalimumab
Adalimumab (USAN/INN)
Adalimumab (genetical recombination)
 
Adalimumab (genetical recombination) (JAN)
D02597
Humira
Humira (TN)
Humira Pen
Ig gamma-1 chain C region
3
Etanerceptapproved, investigationalPhase 4, Phase 3, Phase 2403185243-69-0
Synonyms:
185243-69-0
CD120b
D00742
Enbrel
Enbrel (TN)
Enbrel Sureclick
Etanercept
Etanercept (USAN/INN)
 
Etanercept (genetical recombination)
Etanercept (genetical recombination) (JAN)
TNF-R2
Tumor necrosis factor receptor 2
Tumor necrosis factor receptor superfamily member 1B precursor
Tumor necrosis factor receptor type II
etanercept
p75
p80 TNF-alpha receptor
4
InfliximabapprovedPhase 4, Phase 3, Phase 2392170277-31-3
Synonyms:
 
Ig gamma-1 chain C region
Remicade
5
Certolizumab pegolapprovedPhase 4, Phase 3, Phase 1127428863-50-7
Synonyms:
428863-50-7
CDP870
Certolizumab pegol
 
Certolizumab pegol (USAN/INN)
Certolizumab pegol (genetical recombination)
Certolizumab pegol (genetical recombination) (JAN)
D03441
cimzia
6
Dimethyl fumarateapproved, investigationalPhase 4, Phase 3, Phase 285624-49-7637568, 5271565
Synonyms:
(E)-CH3OC(O)CH=CHC(O)OCH3
(e)-But-2-enedioic acid dimethyl ester
1,2-Bis(methoxycarbonyl)-trans-Ethylene
1,2-Bis(methoxycarbonyl)-trans-ethylene
2-Butenedioic acid (2E)-, 1,4-dimethyl ester
2-Butenedioic acid (2E)-, dimethyl ester
2-Butenedioic acid (E)-, dimethyl ester
2-Butenedioic acid, dimethyl ester
Allomaleic acid dimethyl ester
BG 12 compound
BG-12
Boletic acid dimethyl ester
But-2-enedioic acid, dimethyl ester
Dimethyl (2E)-2-butenedioate
Dimethyl (2E)-but-2-enedioate
Dimethyl (E)-but-2-enedioate
Dimethyl but-2-enedioate
Dimethyl ester(2E)-2-Butenedioic acid
 
Dimethyl ester(E)-2-Butenedioic acid
Dimethyl fumarate
Dimethyl fumarate (usan)
Dimethyl trans-ethylenedicarboxylate
Dimethylester kyseliny fumarove
Dimethylfumarate
Fumaderm
Fumaric acid dimethyl ester
Fumaric acid, dimethyl ester
Fumaric acid, dimethyl ester (8CI)
Maleic acid, dimethyl ester
Methyl fumarate
Tecfidera
Trans-butenedioic acid dimethyl ester
dimethyl (E) butenedioate
trans-1, 2-Ethylenedicarboxylic acid dimethyl ester
trans-1,2-Ethylenedicarboxylic Acid dimethyl ester
trans-1,2-Ethylenedicarboxylic acid dimethyl ester
trans-Butenedioic acid dimethyl ester
7
MethotrexateapprovedPhase 4, Phase 3, Phase 2, Phase 115511959-05-2, 59-05-2126941
Synonyms:
4-amino-10-methylfolic acid
4-amino-N(10)-methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Emtexate
Folex
HDMTX
L-Amethopterin
Ledertrexate
MTX
Metatrexan
 
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate Sodium
Methotrexatum
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
Méthotrexate
N-Bismethylpteroylglutamic Acid
N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Rheumatrex
Trexall
8
MentholapprovedPhase 4, Phase 326062216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
9
BenzocaineapprovedPhase 4, Phase 3, Phase 220161994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Caswell No. 430A
Chloraseptic
D001566
D00552
DB01086
Dermoplast
Diet Ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
 
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Formate, Benzocaine
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
MLS001331704
MLS002153970
Methanesulfonate, Benzocaine
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Norcain
Norcaine
Norcainum
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orthesin
Otocain
Outgro
Parathesin
Parathesin (TN)
Parathesine
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
10
Apremilastapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 175608141-41-911561674
Synonyms:
Apremilast
Apremilast (USAN)
Apremilastum
Aprémilast
CC-10004
 
CHEBI:558773
CHEMBL514800
CID11561674
D08860
N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide
N-{2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide
11
Triamcinoloneapproved, vet_approvedPhase 4510124-94-731307
Synonyms:
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione
11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
124-94-7
4-08-00-03629 (Beilstein Handbook Reference)
83474-03-7
9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-16-alpha-hydroxyprednisolone
9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy
9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-hydroxyprednisolone
9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-16α-hydroxyprednisolone
AC-2072
AC1L1LDH
AC1Q5HJC
Adcortyl
Aristocort
Aristocort A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
BPBio1_000154
BRD-K77554836-001-03-3
BRN 2341955
BSPBio_000140
Bio-0662
C21H27FO6
CHEMBL1451
CID31307
CL 19823
Celeste
Cinolone
Cinolone-T
D00385
D014221
DB00620
Delphicort
EINECS 204-718-7
EU-0101179
Fluoxiprednisolone
Fluoxyprednisolone
Flutex
Fougera
HMS1568G22
HMS2090D12
HSDB 3194
Kenacort
Kenacort (TN)
Kenacort-A
Kenacort-AG
Kenacort-Ag
Kenalog
Kenalog in Orabase
Kenalog-10
Kenalog-40
Kenalog-H
LS-698
Ledercort
Lopac0_001179
 
MLS000028542
MLS001066543
MLS002695935
MolPort-002-528-981
Mycolog
NCGC00021580-03
NCGC00021580-04
NCGC00021580-05
NCGC00021580-06
NCGC00021580-07
NCI60_000750
NSC 13397
NSC13397
Nasacort
Nasacort Aq
Nasacort Hfa
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Pregna-1,4-diene-3,20-dio
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)
Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI)
Prestwick0_000120
Prestwick1_000120
Prestwick2_000120
Prestwick3_000120
Prestwick_438
Rodinolone
S1933_Selleck
SK-Triamcinolone
SMP1_000300
SMR000058333
SPBio_002079
Sk-Triamcinolone
T6376_SIGMA
TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7))
Tiamcinolonum
Tiamcinolonum [INN-Latin]
Tri-Nasal
Triacet
Triacort
Triam-Tablinen
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
Triamcinolone (JP15/USP/INN)
Triamcinolone [USAN:INN:BAN:JAN]
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Triatex
Tricortale
Triderm
Trilone
Tristoject
Trymex
UNII-1ZK20VI6TY
Vetalog
Volon
Volon A
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ
ZINC03882036
droxypregna-1,4-diene-3,20-dione
ione
nchembio.2007.53-comp7
triamcinolone
12
leucovorinapproved, NutraceuticalPhase 4, Phase 3, Phase 2, Phase 1323558-05-954575, 6560146, 143
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formyltetrahydrofolic acid
Acide folinique
Calcium citrovorum factor
Calcium folinate
Citrovorum factor
Folinate
Folinic acid
Folinic acid calcium salt
 
Folinic acid calcium salt USP27
Folinic acid-SF
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
L-Leucovorin
L-N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-Glutamic acid
L-leucovorin
Leucal
Leucovorin calcium
Leucovorin folinic acid
Leucovorinum
Leukovorin
Levoleucovorin
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyl-THF
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Welcovorin
Wellcovorin
folinate
13tannic acidapproved, NutraceuticalPhase 4, Phase 3, Phase 22016
14
Folic Acidapproved, nutraceutical, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1439259-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
15ImmunoglobulinsPhase 4, Phase 3, Phase 2, Phase 16394
16AntibodiesPhase 4, Phase 3, Phase 2, Phase 16394
17Adrenocorticotropic HormonePhase 4164
18Calcium, DietaryPhase 45713
19VaccinesPhase 4, Phase 26611
20Melanocyte-Stimulating HormonesPhase 4139
21Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 123689
22Analgesics, Non-NarcoticPhase 4, Phase 3, Phase 2, Phase 16501
23Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 1, Phase 213168
24HormonesPhase 4, Phase 1, Phase 214415
25beta-endorphinPhase 4140
26Hormone AntagonistsPhase 4, Phase 1, Phase 213180
27Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 2, Phase 110729
28AnalgesicsPhase 4, Phase 3, Phase 2, Phase 111733
29Anti-Inflammatory Agents, Non-SteroidalPhase 4, Phase 3, Phase 2, Phase 14443
30Dermatologic AgentsPhase 4, Phase 3, Phase 2, Phase 15806
31Gastrointestinal AgentsPhase 4, Phase 3, Phase 2, Phase 18402
32Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 113086
33Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 110956
34Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 122062
35Angiogenesis Modulating AgentsPhase 4, Phase 3, Phase 2, Phase 14185
36Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 111226
37glucocorticoidsPhase 4, Phase 1, Phase 25103
38Angiogenesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 14257
39Antibodies, MonoclonalPhase 4, Phase 3, Phase 2, Phase 14039
40Folic Acid AntagonistsPhase 4, Phase 3, Phase 2, Phase 12257
41Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 2, Phase 17361
42AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 112054
43Nucleic Acid Synthesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 14962
44Vitamin B ComplexPhase 4, Phase 3, Phase 2, Phase 14337
45Triamcinolone diacetatePhase 4510
46triamcinolone acetonidePhase 4510
47Triamcinolone hexacetonidePhase 4510
48FolateNutraceuticalPhase 4, Phase 3, Phase 2, Phase 14392
49Vitamin B9NutraceuticalPhase 4, Phase 3, Phase 2, Phase 14392
50
Doxycyclineapproved, investigational, vet_approvedPhase 3243564-25-054671203
Synonyms:
(2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10597-92-9
17086-28-1 (mono-hydrate)
2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)
24390-14-5
41411-66-9 (6-epimer, mono-hydrochloride)
5-Hydroxy-alpha-6-deoxytetracycline
5-hydroxy-α-6-deoxytetracycline
564-25-0
6-Deoxyoxytetracycline
6-Deoxytetracycline
6-alpha-Deoxy-5-oxytetracycline
6-alpha-deoxy-5-oxytetracycline
69935-17-7 (mono-hydrochloride, di-hydrate)
6alpha-Deoxy-5-oxytetracycline
6alpha-deoxy-5-oxytetracycline
6α-deoxy-5-oxytetracycline
7164-70-7
7264-10-0
94088-85-4 (calcium salt (1:2))
AB08 (*Fosfatex)
AC1NQXW7
AC1NS4CW
AC1NUYS8
AC1O8PYM
Alti-Doxycycline
Anhydrous doxycycline
Apo-Doxy
Atridox
Azudoxat
BCBcMAP01_000024
BIDD:GT0146
BMY-28689
BPBio1_000951
BSPBio_000863
BSPBio_001936
BU-3839T
C06973
CHEBI:50845
CHEMBL1433
CID5281011
CID5353597
CID5463943
CID6713981
CPD001550033
D07876
DB00254
DMSC (*Fosfatex)
DOXCYCLINE ANHYDROUS
DOXY
DOXYCYCLINE CALCIUM
DOXYCYCLINE MONOHYDRATE
Deoxymykoin
DivK1c_000345
Dossiciclina
Dossiciclina [DCIT]
Doxcycline anhydrous
Doxiciclina
Doxiciclina [INN-Spanish]
Doxiciclina [Italian]
Doxitard
Doxivetin
Doxy-Caps
Doxy-Puren
Doxy-Tabs
Doxycen
Doxychel
Doxychel (TN)
Doxycin
Doxycyclin
Doxycycline (200mg/day) or Placebo
 
Doxycycline (INN)
Doxycycline (TN)
Doxycycline (anhydrous)
Doxycycline (internal use)
Doxycycline Hyclate
Doxycycline Monohydrate
Doxycycline anhydrous
Doxycycline hyclate
Doxycycline-Chinoin
Doxycyclinum
Doxycyclinum [INN-Latin]
Doxysol
Doxytec
Doxytetracycline
EINECS 209-271-1
GS-3065 (*monohydrate)
HMS2090E06
HSDB 3071
Hydramycin
IDI1_000345
Investin
Jenacyclin
KBio1_000345
KBio2_001287
KBio2_003855
KBio2_006423
KBio3_001156
KBioGR_001133
KBioSS_001287
LS-187766
LS-93868
Liviatin
Lopac0_000405
MolPort-002-507-423
Monodox
Monodox (*monohydrate)
NCGC00161602-01
NCGC00161602-03
NCGC00161602-04
NCGC00167961-01
NCGC00179395-01
NINDS_000345
NSC633557
Novo-Doxylin
Nu-Doxycycline
Oracea
Prestwick0_000852
Prestwick1_000852
Prestwick2_000852
Prestwick3_000852
Ronaxan
SAM002589932
SMP1_000107
SPBio_000246
SPBio_002784
STOCK1N-34341
Spanor
Spectrum2_000143
Spectrum3_000408
Spectrum4_000527
Spectrum5_000947
Spectrum_000807
Supracyclin
UNII-334895S862
UPCMLD-DP021
UPCMLD-DP021:001
Vibra-tabs
Vibramycin
Vibramycin (*monohydrate)
Vibramycin Novum
Vibramycine
Vibravenos
Vivox (*Hyclate)
alpha-6-Deoxy-5-hydroxytetracycline
alpha-6-Deoxyoxytetracycline
alpha-Doxycycline
doxycycline

Interventional clinical trials:

(show top 50)    (show all 287)
idNameStatusNCT IDPhase
1Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic ArthritisUnknown statusNCT01939132Phase 4
2Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing SpondylitisUnknown statusNCT02132234Phase 4
3Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With PsoriasisUnknown statusNCT01223976Phase 4
4Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative ArthritisUnknown statusNCT00573651Phase 4
5The Influence of Adalimumab on Cardiovascular and Metabolic Risk in PsoriasisUnknown statusNCT01088165Phase 4
6A Study in Participants With Psoriatic Arthritis Attending Dermatology ClinicsCompletedNCT02470481Phase 4
7Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology PracticeCompletedNCT01147874Phase 4
8Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic ArthritisCompletedNCT00245960Phase 4
9HUmira in Psoriatic ArthritisCompletedNCT01465438Phase 4
10REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®)CompletedNCT00127842Phase 4
11Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic ArthritisCompletedNCT00432406Phase 4
12An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis ParticipantsCompletedNCT00760669Phase 4
13Enbrel® in Psoriatic ArthritisCompletedNCT00111124Phase 4
14Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in SpainCompletedNCT00195377Phase 4
15National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker StudyCompletedNCT01123265Phase 4
16Study Evaluating Etanercept and Methotrexate in Plaque PsoriasisCompletedNCT00161655Phase 4
17TNFalfa Blocking Treatment of SpondylarthropathiesCompletedNCT00133315Phase 4
18Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNFCompletedNCT01604629Phase 4
19Centocor Microarray Study of PatientsCompletedNCT00462072Phase 4
20Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or FeetCompletedNCT00735787Phase 4
21Study Evaluating Etanercept for the Treatment of Moderate to Severe PsoriasisCompletedNCT00663052Phase 4
22A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose EscalationRecruitingNCT02814175Phase 4
23Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to PlaceboRecruitingNCT02798211Phase 4
24Dosing of Intra-articular Triamcinolone Hexacetonide for Knee Synovitis in Chronic PolyarthritisRecruitingNCT02437461Phase 4
25The NOR-SWITCH StudyActive, not recruitingNCT02148640Phase 4
26A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic ArthritisNot yet recruitingNCT03151551Phase 4
27An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail PsoriasisNot yet recruitingNCT03022617Phase 4
28Vascular Inflammation in Psoriasis - ApremilastNot yet recruitingNCT03082729Phase 4
29A Study to Assess the Safety and Effectiveness of Golimumab in Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing SpondylitisWithdrawnNCT01692457Phase 4
30Treatment With Apremilast in Patients With Psoriatic ArthritisWithdrawnNCT02558361Phase 4
31Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic ArthritisCompletedNCT01087788Phase 3
32A Study of Golimumab in Participants With Active Psoriatic ArthritisCompletedNCT02181673Phase 3
33A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic ArthritisCompletedNCT00051623Phase 3
34TIght COntrol of Psoriatic ArthritisCompletedNCT01106079Phase 3
35A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic ArthritisCompletedNCT01009086Phase 3
36A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic ArthritisCompletedNCT00265096Phase 3
37Safety and Efficacy Study of Apremilast to Treat Psoriatic ArthritisCompletedNCT01925768Phase 3
38A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF AgentsCompletedNCT01077362Phase 3
39Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)CompletedNCT00235885Phase 3
40Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic ArthritisCompletedNCT02024646Phase 3
41Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)CompletedNCT00367237Phase 3
42Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator StudyCompletedNCT01877668Phase 3
43Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF InhibitorsCompletedNCT01882439Phase 3
44Efficacy and Safety Study of Apremilast to Treat Active Psoriatic ArthritisCompletedNCT01172938Phase 3
45Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)CompletedNCT01392326Phase 3
46Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic ArthritisCompletedNCT00195689Phase 3
47Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject EtanerceptCompletedNCT01901185Phase 3
48Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)?CompletedNCT02164214Phase 3
49Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and PsoriasisCompletedNCT00317499Phase 3
50A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)CompletedNCT00427362Phase 3

Search NIH Clinical Center for Psoriatic Arthritis

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: arthritis, psoriatic

Genetic Tests for Psoriatic Arthritis

About this section

Genetic tests related to Psoriatic Arthritis:

id Genetic test Affiliating Genes
1 Psoriatic Arthritis, Susceptibility to27

Anatomical Context for Psoriatic Arthritis

About this section

MalaCards organs/tissues related to Psoriatic Arthritis:

36
Skin, Testes, Bone, T cells, Thyroid, Endothelial, Heart

Publications for Psoriatic Arthritis

About this section

Articles related to Psoriatic Arthritis:

(show top 50)    (show all 1029)
idTitleAuthorsYear
1
Early recognition and detection of juvenile psoriatic arthritis: a call for a standardized approach to screening. (28044348)
2017
2
Umbilical Plaque in Psoriatic Arthritis. (28090061)
2017
3
Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients. (28496328)
2017
4
Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review. (28521047)
2017
5
Recurrent infections in a patient with psoriatic arthritis and hypogammaglobulinemia, treated with conventional and biologic disease-modifying anti-rheumatic drugs-a primary or secondary entity? (28488125)
2017
6
Tumor necrosis factor inhibitors in psoriatic arthritis. (28490202)
2017
7
Evaluation of fatigue and its correlation with quality of life index, anxiety symptoms, depression and activity of disease in patients with psoriatic arthritis. (28507445)
2017
8
Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics. (28493493)
2017
9
Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. (28483767)
2017
10
Association between mean platelet volume and disease severity in patients with psoriasis and psoriatic arthritis. (28507491)
2017
11
Effectiveness of conventional disease-modifying antirheumatic drugs in psoriatic arthritis: A systematic review. (28089501)
2017
12
Pregnancy Outcomes in Patients with Psoriatic Arthritis. (28042130)
2017
13
Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry. (28089969)
2017
14
ERAP1 and ERAP2 Gene Variations Influence the Risk of Psoriatic Arthritis in Romanian Population. (28083616)
2017
15
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. (28473423)
2017
16
The role of IL-17 in the treatment of psoriatic arthritis. (28485176)
2017
17
Psychometric properties of the painDETECT questionnaire in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: Rasch analysis and test-retest reliability. (28532452)
2017
18
Features of some clinical examination parameters in patients with psoriatic arthritis. (28511160)
2017
19
Income disparities in healthcare use remain after controlling for healthcare need: evidence from Swedish register data on psoriasis and psoriatic arthritis. (28527093)
2017
20
A rare coding allele in IFIH1 is protective for psoriatic arthritis. (28501801)
2017
21
Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. (28521824)
2017
22
New Interleukins in Psoriasis and Psoriatic Arthritis Patients: The Possible Roles of Interleukin-33 to Interleukin-38 in Disease Activities and Bone Erosions. (28490011)
2017
23
Economic impact of biologic utilization patterns in patients with psoriatic arthritis. (28474139)
2017
24
Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease. (28052860)
2017
25
Rapid dactylitis resolution in a patient with psoriatic arthritis after treatment with ustekinumab. (28073691)
2017
26
New GRAPPA and EULAR recommendations for the management of psoriatic arthritis: Process and challenges faced. (28077693)
2017
27
Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: Analysis in patients from Central and Eastern Europe. (28506134)
2017
28
Management of psoriatic arthritis (PsA) among cutaneous psoriasis: from pathogenesis to therapy. (28534601)
2017
29
Radiographic scoring instruments have moderate sensitivity but high specificity for detecting change in axial psoriatic arthritis. (28085226)
2017
30
Psoriatic arthritis in Japan: difference in clinical features and approach to precision medicine. (27586804)
2016
31
Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study. (28010883)
2016
32
Performance of screening tools for psoriatic arthritis: a cross-sectional study in primary care. (28013202)
2016
33
Associations between five important domains of health and the Patient Acceptable Symptom State in rheumatoid arthritis and psoriatic arthritis: A cross sectional study of 977 patients. (27998030)
2016
34
A national survey on the management of psoriatic arthritis using the Delphi method. (27607572)
2016
35
Cartilage collagen type II seromarker patterns in axial spondyloarthritis and psoriatic arthritis: associations with disease activity, smoking and HLA-B27. (26620690)
2016
36
Defining Low Disease Activity States in Psoriatic Arthritis Using Novel Composite Disease Instruments. (27587014)
2016
37
Spondyloarthropathies: IL-6 blockade in psoriatic arthritis - a new therapeutic option? (27215204)
2016
38
Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). (27169431)
2016
39
Incidence of Malignancies in a Cohort of Psoriatic Arthritis Patients Taking Traditional Disease Modifying Antirheumatic Drug and Tumor Necrosis Factor Inhibitor Therapy: An Observational Study. (27633825)
2016
40
Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials. (27134249)
2016
41
Interleukin (IL)-9/IL-9R axis drives I^I' T cells activation in psoriatic arthritis patients. (27543964)
2016
42
Risk of cardiovascular morbidity in patients with psoriatic arthritis: A meta-analysis of observational studies. (27111228)
2016
43
Patient-Reported Outcomes in Psoriatic Arthritis. (27133489)
2016
44
Psoriatic arthritis and psoriasis: differential diagnosis. (27156076)
2016
45
Prologue: 2015 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). (27134267)
2016
46
Initial Experience of Using Dual-Energy CT with an Iodine Overlay Image for Hand Psoriatic Arthritis: Comparison Study with Contrast-enhanced MR Imaging. (28045646)
2016
47
Natural history of isolated nail psoriasis and its role as a risk factor for the development of psoriatic arthritis: a single center cross sectional study. (27589338)
2016
48
Implications of the diversity of class I HLA associations in psoriatic arthritis. (27455857)
2016
49
Serum Interleukin-18, Fetuin-A, Soluble Intercellular Adhesion Molecule-1, and Endothelin-1 in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome. (27527149)
2016
50
Detection of subclinical ultrasound enthesopathy and nail disease in patients at risk of psoriatic arthritis. (27932277)
2016

Variations for Psoriatic Arthritis

About this section

Clinvar genetic disease variations for Psoriatic Arthritis:

5
id Gene Variation Type Significance SNP ID Assembly Location
1TNFTNF, -308G-ASNVrisk factor
2LTANM_ 001159740.2(LTA): c.-9-198A> GSNVrisk factorrs909253GRCh37Chr 6, 31540313: 31540313

Expression for genes affiliated with Psoriatic Arthritis

About this section
Search GEO for disease gene expression data for Psoriatic Arthritis.

Pathways for genes affiliated with Psoriatic Arthritis

About this section

Pathways related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

(show all 42)
idSuper pathwaysScoreTop Affiliating Genes
110.0NOD2, TNF, TNFRSF1A
2
Show member pathways
9.9TNF, TNFRSF1A, TNFRSF1B
39.9TNF, TNFRSF1A, TNFRSF1B
49.9TNF, TNFRSF1A, TNFRSF1B
59.8IL1B, SELE, TNF
6
Show member pathways
9.8LTA, TNF, TNFRSF1A, TNFRSF1B
79.8LTA, TNF, TNFRSF1A, TNFRSF1B
8
Show member pathways
9.8IL1B, TNF, TNFRSF11B
99.7IL13, IL1B, TNF
109.7IL13, IL1B, TNF
11
Show member pathways
9.7TNF, TNFRSF1A, TNFRSF1B, TNFSF11
129.6IL1B, SELE, TNF, TNFRSF1A
139.6IL13, IL1B, LTA, TNF
149.6IL1B, TNF, TNFRSF11B, TNFSF11
159.6COMP, IL1B, SELE, TNF
16
Show member pathways
9.5IL1B, LTA, TNF, TNFRSF1A, TNFRSF1B
17
Show member pathways
9.5IL1B, LTA, TNF, TNFRSF1A, TNFRSF1B
18
Show member pathways
9.5HLA-DRB1, IL1B, TNF, TNFRSF1A
19
Show member pathways
9.5IL13, IL1B, MMP3, TNF
20
Show member pathways
9.5LTA, TNF, TNFRSF11B, TNFRSF1A, TNFRSF1B
219.5IL1B, LTA, TNF, TNFRSF1A, TNFSF11
229.4HLA-C, HLA-DRB1, LTA, TNF, TNFRSF1A
23
Show member pathways
9.4HLA-C, IL13, IL1B, LTA, TNF
249.4HLA-DRB1, IL13, IL1B, TNF
259.4IL13, IL1B, LTA, TNF, TNFSF11
269.4CD58, HLA-C, HLA-DRB1, SELE
279.4IL1B, TNF, TNFRSF11B, TNFRSF1A, TNFSF11
28
Show member pathways
9.4IL1B, MMP3, SELE, TNF, TNFRSF1A
299.4HLA-DRB1, IL1B, NOD2, TNF, TNFRSF1A
309.4IL13, IL1B, TNF, TNFRSF1A, TNFRSF1B
319.3IL13, IL1B, MMP3, TNF, TNFRSF1B
32
Show member pathways
9.3LTA, TNF, TNFRSF11B, TNFRSF1A, TNFRSF1B, TNFSF11
339.3HLA-DRB1, IL1B, MMP3, TNF, TNFSF11
34
Show member pathways
9.2HLA-DRB1, IL13, IL1B, NOD2, TNF
359.1IL1B, PTPN22, TNF, TNFRSF1A, TNFRSF1B, TNFSF11
36
Show member pathways
8.9HLA-C, HLA-DRB1, IL13, IL1B, LTA, MICA
378.9IL1B, LTA, MMP3, NOD2, SELE, TNF
38
Show member pathways
8.9IL1B, LTA, TNF, TNFRSF11B, TNFRSF1A, TNFRSF1B
39
Show member pathways
8.8HLA-C, HLA-DRB1, IL13, IL1B, LTA, TNF
40
Show member pathways
8.8IL13, IL1B, LTA, PTPN22, TNF, TNFRSF1A
41
Show member pathways
7.8HLA-C, HLA-DRB1, IL13, IL1B, LTA, MMP3
42
Show member pathways
6.5CD58, CRP, HLA-C, HLA-DRB1, IL13, IL1B

GO Terms for genes affiliated with Psoriatic Arthritis

About this section

Cellular components related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1membrane raftGO:004512110.5SELE, TNF, TNFRSF1A, TNFRSF1B
2cell surfaceGO:00099869.8CD58, HLA-C, HLA-DRB1, MICA, NOD2, TNF
3extracellular spaceGO:00056158.6COMP, CRP, IL13, IL1B, LTA, MICA
4extracellular regionGO:00055768.5COMP, CRP, IL13, IL1B, LTA, MMP3
5plasma membraneGO:00058867.5CD58, HLA-C, HLA-DRB1, LTA, MICA, NOD2

Biological processes related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

(show all 42)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of chronic inflammatory response to antigenic stimulusGO:000287610.9LTA, TNF
2positive regulation of humoral immune response mediated by circulating immunoglobulinGO:000292510.9LTA, TNF
3death-inducing signaling complex assemblyGO:007155010.9TNF, TNFRSF1A
4cellular response to muramyl dipeptideGO:007122510.9NOD2, PTPN22
5negative regulation of lipid storageGO:001088810.9CRP, TNF
6positive regulation of ceramide biosynthetic processGO:200030410.8TNF, TNFRSF1A
7positive regulation of protein K63-linked ubiquitinationGO:190252310.8NOD2, PTPN22
8positive regulation of calcidiol 1-monooxygenase activityGO:006055910.8IL1B, TNF
9positive regulation of chemokine biosynthetic processGO:004508010.8IL1B, TNF
10positive regulation of fever generationGO:003162210.8IL1B, TNF
11positive regulation of heterotypic cell-cell adhesionGO:003411610.8IL1B, TNF
12defense response to Gram-positive bacteriumGO:005083010.7CRP, LTA, TNF
13detection of bacteriumGO:001604510.7HLA-DRB1, NOD2
14cellular response to organic cyclic compoundGO:007140710.7IL1B, NOD2, TNF
15intrinsic apoptotic signaling pathway in response to DNA damageGO:000863010.7TNF, TNFRSF1A, TNFRSF1B
16positive regulation of interferon-gamma productionGO:003272910.6IL1B, LTA, TNF
17apoptotic signaling pathwayGO:009719010.6TNF, TNFRSF11B, TNFRSF1B
18positive regulation of interleukin-6 productionGO:003275510.6IL1B, NOD2, TNF
19positive regulation of interleukin-8 productionGO:003275710.6IL1B, NOD2, TNF
20sequestering of triglycerideGO:003073010.6IL1B, TNF
21positive regulation of membrane protein ectodomain proteolysisGO:005104410.6IL1B, TNF, TNFRSF1B
22lipopolysaccharide-mediated signaling pathwayGO:003166310.6IL1B, PTPN22, TNF
23antigen processing and presentationGO:001988210.6HLA-C, HLA-DRB1, MICA
24defense responseGO:000695210.5NOD2, TNF, TNFRSF1A, TNIP1
25regulation of inflammatory responseGO:005072710.5NOD2, SELE, TNIP1
26regulation of establishment of endothelial barrierGO:190314010.5IL1B, TNF, TNFRSF1A
27cellular response to mechanical stimulusGO:007126010.5IL13, IL1B, TNFRSF1A
28positive regulation of inflammatory responseGO:005072910.4S100A12, TNFRSF1A, TNIP1
29positive regulation of MAP kinase activityGO:004340610.4S100A12, TNF, TNFSF11
30response to nutrientGO:000758410.4LTA, NOD2, TNFRSF11B
31positive regulation of JNK cascadeGO:004633010.4IL1B, NOD2, TNF, TNFSF11
32regulation of apoptotic processGO:004298110.3NOD2, TNFRSF11B, TNFRSF1A, TNFRSF1B
33regulation of cell proliferationGO:004212710.3TNF, TNFRSF11B, TNFRSF1A, TNFRSF1B
34leukocyte migrationGO:005090010.2CD58, IL1B, SELE, TNF
35defense response to bacteriumGO:004274210.2MICA, NOD2, S100A12, TNF, TNFRSF1A
36positive regulation of NF-kappaB transcription factor activityGO:005109210.0IL1B, NOD2, S100A12, TNF, TNFSF11
37apoptotic processGO:00069159.9COMP, IL1B, LTA, TNFRSF11B, TNFRSF1A, TNFRSF1B
38positive regulation of I-kappaB kinase/NF-kappaB signalingGO:00431239.8IL1B, NOD2, S100A12, TNF, TNFRSF1A, TNFSF11
39tumor necrosis factor-mediated signaling pathwayGO:00332099.3LTA, TNF, TNFRSF11B, TNFRSF1A, TNFRSF1B, TNFSF11
40response to lipopolysaccharideGO:00324969.2IL13, IL1B, LTA, PTPN22, SELE, TNFRSF11B
41immune responseGO:00069558.9HLA-C, HLA-DRB1, IL13, IL1B, LTA, TNF
42inflammatory responseGO:00069548.8CRP, IL13, IL1B, S100A12, SELE, TNF

Molecular functions related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1tumor necrosis factor receptor bindingGO:000516410.3LTA, TNF, TNFSF11
2tumor necrosis factor-activated receptor activityGO:00050319.8TNFRSF11B, TNFRSF1A, TNFRSF1B
3cytokine activityGO:00051259.6IL13, IL1B, LTA, TNF, TNFRSF11B, TNFSF11

Sources for Psoriatic Arthritis

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet